David Lebovitz
Stock Analyst at Citigroup
(2.70)
# 1,781
Out of 4,829 analysts
95
Total ratings
87.5%
Success rate
10.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $61.37 | +27.10% | 4 | May 2, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $338 → $351 | $270.19 | +29.91% | 31 | Mar 21, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $300.76 | +55.94% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $33.32 | +122.09% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $45.57 | -16.61% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $46.01 | -63.05% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $100.27 | -8.25% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $58.97 | -8.42% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $33.53 | +4.38% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.59 | +969.18% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $0.73 | +1,399.05% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $154.43 | +28.86% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $6.15 | +7,704.88% | 2 | Nov 3, 2020 |
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $61.37
Upside: +27.10%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $338 → $351
Current: $270.19
Upside: +29.91%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $300.76
Upside: +55.94%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $33.32
Upside: +122.09%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $45.57
Upside: -16.61%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $46.01
Upside: -63.05%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $100.27
Upside: -8.25%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $58.97
Upside: -8.42%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $33.53
Upside: +4.38%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.59
Upside: +969.18%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $0.73
Upside: +1,399.05%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $154.43
Upside: +28.86%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $6.15
Upside: +7,704.88%